header-bd-logo.svg
  • 제품
  • 솔루션
  • 지식 센터
    • 문헌
  • 지원
    • 고객 센터
  • BD 소개
    • 회사 소개
      • 회사 소개
      • 부문
      • 윤리 및 준법
    • BD 사이버 보안
    • ESG(환경, 사회 및 거버넌스)
      • 글로벌 헬스
      • 지속 가능성
      • 사회 공헌
      • 포용과 다양성 및 형평성
    • 글로벌 외부 자금 지원 기회
    • 투자
    • BD의 혁신
      • 개요
      • BD 아이디어 제출 절차
    • 뉴스, 미디어 및 블로그
    • 정책, 지침 및 선언 센터
    • 최근 인수합병
    • 공급업체
      • 기업 정책 및 기대 사항
      • BD와 사업 수행
      • 글로벌 조달
  • 채용
  • header-flag-icon-boosted-blue.svg

    한국

    • North America
      • Canada (EN)
      • Canada (FR)
      • México
      • United States
    • South America
      • Argentina
      • Brasil
      • Chile
      • Colombia
    • Europe
      • Belgique
      • België
      • Česká republika
      • Deutschland
      • España
      • Europe
      • France
      • Hungary
      • ישראל
      • Italia
      • Magyarország
      • Nederland
      • Nordics
      • Österreich
      • Polska
      • Россия
      • Schweiz
      • Türkiye
      • United Kingdom
    • Middle East / Africa
      • Middle East, North Africa
      • South Africa
    • Asia / Pacific
      • Australia / New Zealand
      • 中国
      • Greater Asia
      • India
      • 日本
      • 대한민국
      • South East Asia
  • header-flag-icon-boosted-blue.svg

    한국

    North America
    • Canada (EN)
    • Canada (FR)
    • México
    • United States
    South America
    • Argentina
    • Brasil
    • Chile
    • Colombia
    Europe
    • Belgique
    • België
    • Česká republika
    • Deutschland
    • España
    • Europe
    • France
    • Hungary
    • ישראל
    • Italia
    • Magyarország
    • Nederland
    • Nordics
    • Österreich
    • Polska
    • Россия
    • Schweiz
    • Türkiye
    • United Kingdom
    Middle East / Africa
    • Middle East, North Africa
    • South Africa
    Asia / Pacific
    • Australia / New Zealand
    • 中国
    • Greater Asia
    • India
    • 日本
    • 대한민국
    • South East Asia
true
Products

MaxPlus™ and MaxZero™ Needle-free Connector

Demonstrated in 10 peer-reviewed published studies to reduce catheter-related complications

maxzero-maxplus-hero.jpg
Loading
  1. Overview
  2. Results and Clinical Studies
  3. Products & Accessories
  4. eIFU & Resources
Overview

The MaxPlus™ and MaxZero™ Needle-free Connector technology is designed to help reduce the risk of infections and occlusions.

Features and Benefits

The differentiated MaxPlus™ and MaxZero™ Needle-free Connector technology has been helping facilities reduce central line-associated bloodstream infections (CLABSIs) and occlusions for over 10 years1–10

 Nam sodales urna sed

lower risk of CLABSI1

The MaxPlus™ Needle-free Connector was shown to reduce the risk of CLABSI by 63%, compared to other needle-free connectors, in a 2014 meta-analysis published in the American Journal of Infection Control1

Sodales urna sed

reduction in occlusions2

In a retrospective observational study of 720 home infusion patients, the MaxZero™ Needle-free Connector reduced PICC^ occlusion rates by 55.1% (p=0.001), compared to a leading neutral displacement connector2

^ PICC: Peripherally Inserted Central Catheter.

Others claim to reduce CLABSIs. We let the clinical evidence speak for us.

img

The BD MaxPlus™ Needle-free Connector is the only needle-free connector with an FDA-cleared label statement demonstrating a reduction in CLABSIs11

 

2013 CMS Hospital Compare data reported by 3,075 U.S. hospitals, accounting for nearly 11,000 CLABSIs associated with nearly 10 million catheter days, show that hospitals using the MaxPlus™ Needle-free Connector had lower unadjusted CLABSI rates, as well as lower standardized infection ratios, compared to hospitals not using the MaxPlus™ Needle-free Connector.1,3

Not all connectors are created equal

Explore the design innovations that differentiate MaxPlus™ and MaxZero™ Needle-free Connector technology—and how they can help you reduce catheter-related complications, compared to other needle-free connector designs

Upgrade to clinically proven needle-free connectors1–10 and catheters14,15

The needle-free connector you choose impacts the rate of catheter-related complications in your facility.16,17 Refer to our clinical evidence compendium for real-world evidence of helping facilities reduce catheter-related complications.1-10 Explore the design innovations that differentiate MaxPlus™ and MaxZero™ Needle-free Connector technology—and how they can help you reduce catheter-related complications, compared to other needle-free connector designs.

BD Vascular Access Management AllPoints™ Assessments

Our powerful evidence-based assessments, with analytics and benchmarks, are the first phase of BD Vascular Access Management—and the first step on the path to help you reduce complications and improve patient care.

  • Learn more forward arrow
clinician-discussion.jpg

Related Solutions

Evidence-based guidelines recommending the use of needle-free connectors

quote-icon

Evaluate published outcomes of infection risks associated with each type of needleless connector

when making product purchase decisions, focusing on risks, benefits and educational requirements.

—

Infusion Nurses Society (INS) 2021 Infusion Therapy Standards of Practice12


quote-icon

Use needleless connectors (NC) as IV connection devices.

Use a luer-lock mechanism to ensure a secure junction when attaching NC to a VAD or access site. Avoid three-way stopcocks as IV connection devices.

—

International Nosocomial Infection Control Consortium (INICC) 2017 Care Bundles to Prevent Central and Peripheral Line-Related Bloodstream Infections13


Explore the results and clinical studies below to learn more about the evidence supporting MaxPlus™ and MaxZero™ Needle-free Connector technology

63-lower-risk-clabsis.jpg
Meta-analysis

The MaxPlus™ Needle-free Connector was shown to reduce the risk of CLABSI by 63%, compared to other needle-free connectors, in a 2014 peer-reviewed meta-analysis reporting on 7 studies, published in the American Journal of Infection Control,1 and is associated with lower CLABSI risk, independent of seasonality, case mix index, infusion care and cleaning practices.1

lower-clabsis-infection-ratios.jpg
Systematic review

A systematic review of 2013 CMS Hospital Compare data from 3,074 hospitals, accounting for nearly 11,000 CLABSIs associated with nearly 10 million catheter days, shows that hospitals using the MaxPlus™ Needle-free Connector had lower unadjusted CLABSI rates, as well as lower standardized infection ratios, compared to hospitals not using the MaxPlus™ Needle-free Connector.1

 

55-reduction-occlusions.jpg
Retrospective/Prospective Occlusion Study

In a retrospective observational study of 720 home infusion patients, the MaxZero™ Needle-free Connector reduced PICC occlusion rates by 55.1% (p=0.001), compared to a leading neutral displacement connector.2 There was a 55.1% reduction in the total number of nurse visits per 100 central line-days and a 56.4% reduction in Alteplase use and associated cost, after patients were switched to the MaxZero™ Needle-free Connectors.2

70-reduction-clabsis-pediatric.jpg
Retrospective/Prospective CLABSI Studies

A multidisciplinary evidence-based initiative consisting of a CVL insertion, access and maintenance bundle, including implementation of the MaxPlus™ Needle-free Connector, resulted in a reduction in CLABSIs from an estimated 7.8 CLABSIs per 1000 catheter days to 2.3 CLABSIs per 1000 catheter days.4

reduced-clabsis-icu.jpg
Retrospective/Prospective CLABSI Studies

An ICU in a suburban Baltimore hospital reduced CLABSI rates to zero in 2012, by revising its CVAD policies and initiatives and implementing a bundled approach, including the use of MaxPlus™ Needle-free Connectors.5

Products & Accessories
RELATED PRODUCTS NOT AVAILABLE

Manual entered skus

Other products you might be interested in

  • Swabstick
  • Related Product Family 02
  • Related Product Family 03
  • Related Product Family 04
Resources
Case-Study.png
Case Studies

BD promotes clinical excellence by providing various infusion resources on best practices, clinical innovations and industry trends.

Learn more
Event Icon
Literature

BD's collection of literature on our infusion offerings gives you information you can use to continue striving for excellence.

Learn more
Training-Icon1.png
Training

BD offers infusion training resources to help improve your clinical practices as part of our goal of advancing the world of health.

Learn more
Event Icon
Events

BD supports and attends healthcare industry events with market-leading products and services that aim to improve care while lowering costs.

Learn more

Please let us know the areas that you are interested in:

MaxPlus™ and MaxZero™ Needle-free Connector
Ready to learn more? Let’s have a conversation.
Reference
  1. Tabak YP, Jarvis WR, Sun X, Crosby CT, Johannes RS. Meta-analysis on central line-associated bloodstream infections associated with a needleless intravenous connector with a new engineering design. Am J Infect Control. 2014;42(12):1278–1284. doi: 10.1016/j.ajic.2014.08.018.
  2. Williams A. Catheter occlusion in home infusion: the influence of needleless connector design on central catheter occlusion. J Infus Nurs. 2018;41(1):52–57. doi: 10.1097/NAN.0000000000000259.
  3. Tabak YP, Johannes RS, Sun X, Crosby CT, Jarvis WR. Innovative use of existing public and private data sources for postmarketing surveillance of central line-associated bloodstream infections associated with intravenous needleless connectors. J Infus Nurs. 2016;39(5):328–335. doi: 10.1097/NAN.0000000000000185.
  4. Costello JM, Morrow DF, Graham DA, Potter-Bynoe G, Sandora TJ, Laussen PC. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit. Pediatrics. 2008;121(5):915–923. doi: 10.1542/peds.2007-1577.
  5. Wallace MC, Macy DL. Reduction of central line-associated bloodstream infection rates in patients in the adult intensive care unit. J Infus Nurs. 2016;39(1):47–55. doi: 10.1097/NAN.0000000000000151.
  6. Sandora TJ, Graham DA, Conway M, Dodson B, Potter-Bynoe G, Margossian SP. Impact of needleless connector change frequency on central line-associated bloodstream infection rate. Am J Infect Control. 2014;42(5):485–489. doi: 10.1016/j.ajic.2014.01.022.
  7. Royer T. Implementing a better bundle to achieve and sustain a zero central line-associated bloodstream infection rate. J Infus Nurs. 2010;33(6):398–406. doi: 10.1097/NAN.0b013e3181f8586b.
  8. Casey AL, Karpanen TJ, Nightingale P, Chaganti S, Elliott TSJ. Microbiologic contamination of a positive- and a neutral-displacement needleless intravenous access device in clinical use. Am J Infect Control. 2016;44(12):1678–1680. doi: 10.1016/j.ajic.206.06.027.
  9. Clavier T, Ferguen M, Gouin P, et al. Impact of MaxZero™ needle-free connector on the incidence of central venous catheter-related infections in surgical intensive care unit. Aust Crit Care. 2019;32(2):107–111. doi: 10.1016/j.aucc.2018.03.003.
  10. Hankins R, Majorant OD, Rupp ME, et al. Microbial colonization of intravascular catheter connectors in hospitalized patients. Am J Infect Control. 2019;47(12):1489–1492. doi: 10.1016/j.ajic.2019.05.024.
  11. BD MaxPlus™ Needle-free Connector Directions for Use. 630-00658; 2015.
  12. Gorski LA, Hadaway L, Hagle ME, et al. Infusion Therapy Standards of Practice, 8th Edition. J Infus Nurs. 2021;44(1S,1):S1–S224. doi: 10.1097/NAN.0000000000000396.
  13. International Nosocomial Infection Control Consortium (INICC) Care bundles to prevent central and peripheral line-related bloodstream infections. INICC website. http://www.inicc.org/media/docs/2017-INICCBSIPreventionGuidelines.pdf. Published January 1, 2017. Accessed June 2, 2021.
  14. González López J, Arribi Vilela A, Fernández Del Palacio E, et al. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. J Hosp Infect. 2014;86(2):117–126. doi: 10.1016/j.jhin.2013.10.008.
  15. Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabilization systems. J Infus Nurs. 2010;33(6):371–384.doi: 10.1097/NAN.0b013e3181f85be2.
  16. Hadaway L. Needleless connectors for IV catheters. Am J Nurs. 2012;112(11):32–44. doi: 10.1097/01.NAJ.0000422253.72836.c1.
  17. Curran E. Needleless connectors: the vascular access catheter’s microbial gatekeeper. J Infect Prev. 2016;17(5):234–240. doi: 10.1177/1757177416657164.
  18. † Guenezan J, Marjanovic N, Drugeon B, et al. Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial. Lancet Infect Dis. 2021. doi: 10.1016/S1473-3099(20)30738-6.

* Compared to the standard of care that included a standard peripheral catheter and three way stopcock among other elements.

BD-25572 (01/23)  

  • 팔로우하기
    • Linked In
    • Facebook
    • Twitter
    • Youtube
빠른 링크
  • 리콜 및 현장 조치
  • 채용
  • 사이버 보안
  • 전자 사용 지침
  • 이벤트
  • 투자
  • 포용과 다양성 및 형평성
  • 문헌
  • 라이브 채팅 지원
  • 뉴스, 미디어 및 블로그
  • 회사 소개
  • 윤리 및 준법
  • 지원
  • 당사로 문의하기
  • 쿠키 기본 설정
  • 개인정보
  • 이용 약관
  • 개인정보처리방침
  • 웹사이트 접근성
BD_tag_en_1-Color_Reverse_RGB_TransparentBurst

© 2025 BD. 모든 권리 보유. BD와 BD 로고는 Becton, Dickinson and Company의 상표입니다. 기타 모든 상표는 해당 소유주의 자산입니다.

true
MaxPlus™ and MaxZero™ Needle-free Connector Demonstrated in 10 peer-reviewed published studies to reduce catheter-related complications BD MaxPlus™ /content/dam/bd-assets/bd-com/en-us/logos/bd/header-bd-logo.svglogo

Demonstrated in 10 peer-reviewed published studies to reduce catheter-related complications

/ko-kr/products-and-solutions/products/product-brands/maxplus-and-maxzero-needle-free-connector